Latest revenue
$169.1M
as of 2025-09-30
Latest net income
$17.3M
as of 2025-09-30
Net margin
10.2%
as of 2025-09-30
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $4.55B
- Enterprise value
- $4.55B
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $14.50
- 52-wk low
- $5.51
- Beta
- —
- Shares out
- 314.0M
5-year trend
What this company does
Item 1. BUSINESS Overview We are a global, patient-dedicated biotechnology company focused on discovering, developing, and delivering novel medicines for rare diseases. We seek to deliver the highest quality therapies that have the potential to obsolete current treatments, provide significant benefits to patients, and be first- or best-in-class. Our two marketed therapies are Galafold®, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti™ + Opfolda™, a novel treatment designed to improve uptake of active enzyme into key disease relevant tissues for adults living with late-onset Pompe disease. Galafold® (also referred to as…
AI summary unavailable — showing raw filing excerpt
Generated from FOLD's filing dated 2024-02-28
Key risks
Table of Contents ITEM 1A. RISK FACTORS You should carefully consider these risk factors, together with all of the other information included in this Annual Report on Form 10-K, including our Consolidated Financial Statements and the related notes thereto, before you decide whether to make an investment in our securities. The risks set forth below are not the only risks we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially and adversely affect our business, prospects, financial condition, cash flows, liquidity, funds from operations, results of operations, stock price and ability to service our indebtedness. In…
AI summary unavailable — showing raw filing excerpt
Generated from FOLD's filing dated 2024-02-28
Profitability
Gross margin
88.5%
1.6%Operating margin
5.2%
9.8%Net margin
-4.3%
59.8%Return on equity
-14.0%
51.7%Return on assets
-2.9%
60.1%Leverage
Debt / equity
3.90×
27.9%Long-term debt / equity
2.02×
0.7%Debt / assets
79.6%
5.7%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q4 2025 2025-12-31 | $185.2M | +23.7% | $1.7M | -88.5% | 0.9% |
Q3 2025 2025-09-30 | $169.1M | +19.5% | $17.3M | +357.2% | 10.2% |
Q2 2025 2025-06-30 | $154.7M | +22.1% | $-24.4M | -55.6% | -15.8% |
Q1 2025 2025-03-31 | $125.2M | +13.4% | $-21.7M | +55.2% | -17.3% |
Q4 2024 2024-12-31 | $149.7M | — | $14.7M | — | 9.8% |
Q3 2024 2024-09-30 | $141.5M | +36.7% | $-6.7M | +68.8% | -4.8% |
Q2 2024 2024-06-30 | $126.7M | +34.0% | $-15.7M | +63.7% | -12.4% |
Q1 2024 2024-03-31 | $110.4M | — | $-48.4M | — | -43.9% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on FOLD — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$5.4M
Net activity
−$5.4M
Distinct insiders
4
Open-market trades over the last 365 days.
Recent transactions
| Date | Insider | Type | Shares | Price | Value |
|---|
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns FOLD
Institutional value
$1.77B
Total shares held
124.4M
Distinct holders
153
-175 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 33.9M | $489.9M | +1.4M (+4.2%) | Added |
| 2 | UBS Group AG | 16.0M | $230.8M | +10.1M (+170.8%) | Added |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 14.0M | $202.8M | — | New |
| 4 | VANGUARD PORTFOLIO MANAGEMENT LLC | 14.0M | $202.1M | — | New |
| 5 | JPMORGAN CHASE & CO | 6.7M | $97.4M | +3.0M (+81.6%) | Added |
| 6 | CITIGROUP INC | 4.2M | $61.1M | +2.6M (+156.4%) | Added |
| 7 | Magnetar Financial LLC | 4.0M | $57.6M | +18.1K (+0.5%) | Added |
| 8 | Nuveen, LLC | 2.3M | $33.3M | -2.3M (-50.3%) | Trimmed |
| 9 | VANGUARD FIDUCIARY TRUST CO | 2.1M | $30.9M | — | New |
| 10 | BNP PARIBAS FINANCIAL MARKETS | 1.9M | $27.0M | -387.1K (-17.2%) | Trimmed |
| 11 | CIBRA Capital Ltd | 1.7M | $24.4M | +1.5M (+700.6%) | Added |
| 12 | ALPINE ASSOCIATES MANAGEMENT INC. | 1.6M | $23.1M | +647.0K (+68.2%) | Added |
| 13 | Allianz Asset Management GmbH | 1.4M | $20.8M | -45.3K (-3.0%) | Trimmed |
| 14 | GARDNER LEWIS ASSET MANAGEMENT L P | 1.4M | $20.5M | — | New |
| 15 | Alberta Investment Management Corp | 1.4M | $20.1M | -489.2K (-26.0%) | Trimmed |
| 16 | PICTON MAHONEY ASSET MANAGEMENT | 1.3M | $19.2M | +715.7K (+116.3%) | Added |
| 17 | Pictet Asset Management Holding SA | 893.9K | $12.9M | -1.1M (-55.2%) | Trimmed |
| 18 | Bank of New York Mellon Corp | 811.4K | $11.7M | -18.6K (-2.2%) | Trimmed |
| 19 | CREDIT INDUSTRIEL ET COMMERCIAL | 771.9K | $11.2M | +531.9K (+221.6%) | Added |
| 20 | Connor, Clark & Lunn Investment Management Ltd. | 747.5K | $10.8M | -470.5K (-38.6%) | Trimmed |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once FOLD's latest filing finishes processing.